Substance / Medication

Ethionamide

Overview

Active Ingredient
ethionamide
RxNorm CUI
4127

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Pillay Samantha, Steingart Karen R, Davies Geraint R et al. · Cochrane Database Syst Rev · 2022
PMID: 35583175Meta-AnalysisFull text (PMC)
Investigation of drug regimens and treatment outcome in patients with: a systematic review.
Dashtbin Shirin, Mirkalantari Shiva, Dadashi Masoud et al. · Expert Rev Anti Infect Ther · 2022
PMID: 35306950Meta-Analysis
The global outbreak of Mycobacterium chimaera infections in cardiac surgery-a systematic review of whole-genome sequencing studies and joint analysis.
Schreiber Peter W, Kohl Thomas A, Kuster Stefan P et al. · Clin Microbiol Infect · 2021
PMID: 34298175Meta-Analysis
Medical Tourism and Postoperative Infections: A Systematic Literature Review of Causative Organisms and Empiric Treatment.
Padilla Pablo, Ly Priscilla, Dillard Rachel et al. · Plast Reconstr Surg · 2018
PMID: 30489537Meta-Analysis
Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases.
Lehloenya Rannakoe J, Muloiwa Rudzani, Dlamini Sipho et al. · J Antimicrob Chemother · 2015
PMID: 26142408RCT
A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy.
Fajardo Tranquilino T, Guinto Ricardo S, Cellona Roland V et al. · Am J Trop Med Hyg · 2006
PMID: 16525107RCT
Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.
Auclair B, Nix D E, Adam R D et al. · Antimicrob Agents Chemother · 2001
PMID: 11181366TrialFull text (PMC)
Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations.
Conte J E, Golden J A, McQuitty M et al. · Antimicrob Agents Chemother · 2000
PMID: 10770772TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ethionamide (substance)
SNOMED CT
32800009
UMLS CUI
C0015021
RxNorm CUI
4127

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.